<DOC>
	<DOCNO>NCT00332969</DOCNO>
	<brief_summary>This study investigate efficacy treatment octroetide patient primary inoperable thymoma reduce tumor size .</brief_summary>
	<brief_title>Efficacy Octreotide Treatment Patients With Primary Inoperable Thymoma</brief_title>
	<detailed_description />
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Male female patient age &gt; 18 year 2 . Inoperability thymic tumor . Inoperability define least adherence tumor neighbour organ , suspicious infiltrate neighbour organ R0 resection expect . 3 . Positive result SMSszintigraphy , 4 . Thymomas WHO base histological subtypes ( Rosai , 1999 ; Travis 2004 ) Masaoka stage III base histological examination core biopsy resection specimen . 5 . Patients without thymoma associate paraneoplastic syndrome 6 . Demonstrated tolerance test dose s.c. octreotide injection Visit 1 . 1 . Performance status 0,1 , 2 ( ECOG ) 2 . Symptomatic cholelithiasis , 3 . Pretreatment octreotide ( longn act release ) within 3 month 4 . Patient receive investigational agent within 28 day first day study drug dose 5 . Patient &lt; 5 year free another primary malignancy except : primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow 6 . Grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Open label</keyword>
	<keyword>phase II</keyword>
	<keyword>disease</keyword>
	<keyword>clinical trial</keyword>
	<keyword>Octreotide</keyword>
	<keyword>thymoma</keyword>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
</DOC>